Bionik Laboratories Corp. Price & Performance (BNKL)

FibroBiologics announced it has completed the master cell bank for its fibroblast-based CYWC628 therapy, paving the way for a Phase 1/2 trial in Australia targeting diabetic foot ulcers later this year. The company also filed a new patent focused on mitochondrial activity, strengthening its pipeline in chronic disease therapeutics.1

Biodesix reported a 21% year-over-year revenue increase for Q1 2025, reaching $18 million, with gross margins climbing to nearly 80%. Operational improvements and a restructured sales strategy have led the company to reaffirm guidance for positive adjusted EBITDA by year-end, despite a slight delay in commercial expansion.2

The 75th Regeneron International Science and Engineering Fair concluded with more than $9 million distributed to student scientists globally. The event spotlighted groundbreaking research and innovation from teens, furthering the next generation’s involvement in STEM fields and reinforcing the importance of science competitions on a global stage.3